IN2013MU03370A - - Google Patents

Download PDF

Info

Publication number
IN2013MU03370A
IN2013MU03370A IN3370MU2013A IN2013MU03370A IN 2013MU03370 A IN2013MU03370 A IN 2013MU03370A IN 3370MU2013 A IN3370MU2013 A IN 3370MU2013A IN 2013MU03370 A IN2013MU03370 A IN 2013MU03370A
Authority
IN
India
Prior art keywords
self
delivery system
drug delivery
emulsifying drug
pharmaceutically acceptable
Prior art date
Application number
Inventor
Geena Malhotra
Shrinivas Madhukar Purandare
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Priority to IN3370MU2013 priority Critical patent/IN2013MU03370A/en
Priority to PCT/GB2014/053142 priority patent/WO2015059466A1/en
Publication of IN2013MU03370A publication Critical patent/IN2013MU03370A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A pharmaceutical composition comprises a self-emulsifying drug delivery system, wherein the self-emulsifying drug delivery system comprises efavirenz and one or more pharmaceutically acceptable excipients.
IN3370MU2013 2013-10-25 2014-10-22 IN2013MU03370A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IN3370MU2013 IN2013MU03370A (en) 2013-10-25 2014-10-22
PCT/GB2014/053142 WO2015059466A1 (en) 2013-10-25 2014-10-22 Pharmaceutical compositions comprising efavirenz

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN3370MU2013 IN2013MU03370A (en) 2013-10-25 2014-10-22

Publications (1)

Publication Number Publication Date
IN2013MU03370A true IN2013MU03370A (en) 2015-09-25

Family

ID=51947382

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3370MU2013 IN2013MU03370A (en) 2013-10-25 2014-10-22

Country Status (2)

Country Link
IN (1) IN2013MU03370A (en)
WO (1) WO2015059466A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019003150A2 (en) 2017-06-30 2019-01-03 Viiv Healthcare Company Combination and uses and treatments thereof
ES2732498B2 (en) * 2018-05-21 2020-04-27 Consejo Superior Investigacion USE OF EFAVIRENZ FOR THE TREATMENT OF DISEASES OF LIPID STORAGE.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72207C2 (en) 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Pharmaceutical formulations of efavirenz and disintegrants providing for increasing dissolution rate and process of manufacturing such tablets or capsules
PE20000559A1 (en) 1998-05-27 2000-07-05 Merck & Co Inc FORMULATION OF EFAVIRENZ COMPRESSED TABLETS
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
BR112012026843A2 (en) 2010-04-20 2016-07-12 Cipla Ltd composition, pharmaceutical composition, process for preparing a pharmaceutical composition, use of a composition and method for treating HIV

Also Published As

Publication number Publication date
WO2015059466A1 (en) 2015-04-30

Similar Documents

Publication Publication Date Title
MX2023000320A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion.
PH12017502431A1 (en) Pharmaceutical formulations comprising tenofovir and emtrictabine
EP3272387A4 (en) Drug administration device, and manufacturing method for drug administration device
EP3445416A4 (en) Enteral drug delivery system
EP3313499A4 (en) Devices, systems and methods for enhancing intraluminal drug delivery and uptake
PH12019501076A1 (en) Pharmaceutical formulations
PH12016501841A1 (en) Immunosuppressant formulation
MX2017016802A (en) Pharmaceutical formulations.
EP3664885A4 (en) Transdermal drug delivery system
EP3710079A4 (en) Systems, devices, formulations and methods for controlled drug delivery
IL273704A (en) Bi-layer pharmaceutical tablet formulation
EP3801703A4 (en) Tissue integrated drug delivery system
EP3373977A4 (en) Cell-penetrating, guanidinium-rich oligophosphotriesters for drug and probe delivery
IN2013MU01985A (en)
EP3534987A4 (en) Adjustable dose drug delivery system
EP3288544A4 (en) Hypromellose-graft-chitosan and methods thereof for sustained drug delivery
EA201991265A1 (en) MEDICINAL FORMS WITH DELAYED DELIVERY CONTAINING DIMETHYLFUMARATE
EP4049698A4 (en) Drug delivery device
IN2013MU03370A (en)
IL275664A (en) Drug delivery system
EP3925647A4 (en) Drug solution administration device
IN2014MU00043A (en)
WO2019059868A3 (en) Pharmaceutical combinations comprising tenofovir, emtricitabine and efavirenz
EP3760249A4 (en) Drug solution administration device
EP3733243A4 (en) Drug administration method